{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:38:00Z","timestamp":1789616280297,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013238","name":"Faculty of Medicine Siriraj Hospital, Mahidol University","doi-asserted-by":"publisher","award":["R0162330270"],"award-info":[{"award-number":["R0162330270"]}],"id":[{"id":"10.13039\/501100013238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Backgrounds<\/jats:title>\n                    <jats:p>Non-valvular atrial fibrillation (AF) is the most common type of cardiac arrhythmia. AF is caused by electrophysiological abnormalities and alteration of atrial tissues, which leads to the generation of abnormal electrical impulses. Extracellular vesicles (EVs) are membrane-bound vesicles released by all cell types. Large EVs (lEVs) are secreted by the outward budding of the plasma membrane during cell activation or cell stress. lEVs are thought to act as vehicles for miRNAs to modulate cardiovascular function, and to be involved in the pathophysiology of cardiovascular diseases (CVDs), including AF. This study identified lEV-miRNAs that were differentially expressed between AF patients and non-AF controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>lEVs were isolated by differential centrifugation and characterized by Nanoparticle Tracking Analysis (NTA), Transmission Electron Microscopy (TEM), flow cytometry and Western blot analysis. For the discovery phase, 12 AF patients and 12 non-AF controls were enrolled to determine lEV-miRNA profile using quantitative reverse transcription polymerase chain reaction array. The candidate miRNAs were confirmed their expression in a validation cohort using droplet digital PCR (30 AF, 30 controls). Bioinformatics analysis was used to predict their target genes and functional pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      TEM, NTA and flow cytometry demonstrated that lEVs presented as cup shape vesicles with a size ranging from 100 to 1000\u00a0nm. AF patients had significantly higher levels of lEVs at the size of 101\u2013200\u00a0nm than non-AF controls. Western blot analysis was used to confirm EV markers and showed the high level of cardiomyocyte expression (Caveolin-3) in lEVs from AF patients. Nineteen miRNAs were significantly higher (&gt;\u2009twofold,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) in AF patients compared to non-AF controls. Six highly expressed miRNAs (miR-106b-3p, miR-590-5p, miR-339-3p, miR-378-3p, miR-328-3p, and miR-532-3p) were selected to confirm their expression. Logistic regression analysis showed that increases in the levels of these 6 highly expressed miRNAs associated with AF. The possible functional roles of these lEV-miRNAs may involve in arrhythmogenesis, cell apoptosis, cell proliferation, oxygen hemostasis, and structural remodeling in AF.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Increased expression of six lEV-miRNAs reflects the pathophysiology of AF that may provide fundamental knowledge to develop the novel biomarkers for diagnosis or monitoring the patients with the high risk of AF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-021-03213-6","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T05:05:23Z","timestamp":1641186323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Increased expression of six-large extracellular vesicle-derived miRNAs signature for nonvalvular atrial fibrillation"],"prefix":"10.1186","volume":"20","author":[{"given":"Panjaree","family":"Siwaponanan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontawee","family":"Kaewkumdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilasinee","family":"Phromawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suthipol","family":"Udompunturak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nusara","family":"Chomanee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamol","family":"Udol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kovit","family":"Pattanapanyasat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rungroj","family":"Krittayaphong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,3]]},"reference":[{"issue":"5","key":"3213_CR1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373\u2013498.","journal-title":"Eur Heart J"},{"issue":"8","key":"3213_CR2","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1172\/JCI46315","volume":"121","author":"R Wakili","year":"2011","unstructured":"Wakili R, et al. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest. 2011;121(8):2955\u201368.","journal-title":"J Clin Invest"},{"issue":"3","key":"3213_CR3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10557-017-6736-z","volume":"31","author":"NWE van den Berg","year":"2017","unstructured":"van den Berg NWE, et al. MicroRNAs in atrial fibrillation: from expression signatures to functional implications. Cardiovasc Drugs Ther. 2017;31(3):345\u201365.","journal-title":"Cardiovasc Drugs Ther"},{"key":"3213_CR4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2015.05.001","volume":"87","author":"SM Hammond","year":"2015","unstructured":"Hammond SM. An overview of microRNAs. Adv Drug Deliv Rev. 2015;87:3\u201314.","journal-title":"Adv Drug Deliv Rev"},{"issue":"D1","key":"3213_CR5","doi-asserted-by":"crossref","first-page":"D68","DOI":"10.1093\/nar\/gkt1181","volume":"42","author":"A Kozomara","year":"2014","unstructured":"Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014;42(D1):D68-73.","journal-title":"Nucleic Acids Res"},{"key":"3213_CR6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fgene.2013.00119","volume":"4","author":"A Turchinovich","year":"2013","unstructured":"Turchinovich A, et al. Circulating miRNAs: cell-cell communication function? Front Genet. 2013;4:119.","journal-title":"Front Genet"},{"issue":"2","key":"3213_CR7","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3390\/ijms17020170","volume":"17","author":"H Kalra","year":"2016","unstructured":"Kalra H, Drummen GP, Mathivanan S. Focus on extracellular vesicles: introducing the next small big thing. Int J Mol Sci. 2016;17(2):170.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3213_CR8","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/jvim.12128","volume":"27","author":"JM Herring","year":"2013","unstructured":"Herring JM, McMichael MA, Smith SA. Microparticles in health and disease. J Vet Intern Med. 2013;27(5):1020\u201333.","journal-title":"J Vet Intern Med"},{"key":"3213_CR9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41420-020-00305-y","volume":"6","author":"S Fu","year":"2020","unstructured":"Fu S, et al. Extracellular vesicles in cardiovascular diseases. Cell Death Discov. 2020;6:68.","journal-title":"Cell Death Discov"},{"issue":"4","key":"3213_CR10","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/cvr\/cvs007","volume":"93","author":"P Diehl","year":"2012","unstructured":"Diehl P, et al. Microparticles: major transport vehicles for distinct microRNAs in circulation. Cardiovasc Res. 2012;93(4):633\u201344.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"3213_CR11","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3390\/cells9041044","volume":"9","author":"M Groot","year":"2020","unstructured":"Groot M, Lee H. Sorting mechanisms for MicroRNAs into extracellular vesicles and their associated diseases. Cells. 2020;9(4):1044.","journal-title":"Cells"},{"issue":"1","key":"3213_CR12","doi-asserted-by":"crossref","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","volume":"7","author":"C Th\u00e9ry","year":"2018","unstructured":"Th\u00e9ry C, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1535750.","journal-title":"J Extracell Vesicles"},{"issue":"12","key":"3213_CR13","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/clc.23461","volume":"43","author":"Z Wei","year":"2020","unstructured":"Wei Z, et al. Expression of miRNAs in plasma exosomes derived from patients with atrial fibrillation. Clin Cardiol. 2020;43(12):1450\u20139.","journal-title":"Clin Cardiol"},{"issue":"5","key":"3213_CR14","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1096\/fj.201801758R","volume":"33","author":"D Mun","year":"2019","unstructured":"Mun D, et al. Expression of miRNAs in circulating exosomes derived from patients with persistent atrial fibrillation. FASEB J. 2019;33(5):5979\u201389.","journal-title":"FASEB J"},{"issue":"10","key":"3213_CR15","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.21037\/jtd.2019.09.50","volume":"11","author":"S Wang","year":"2019","unstructured":"Wang S, et al. Differentially expressed miRNAs in circulating exosomes between atrial fibrillation and sinus rhythm. J Thorac Dis. 2019;11(10):4337\u201348.","journal-title":"J Thorac Dis"},{"issue":"6","key":"3213_CR16","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001249","volume":"3","author":"F Jansen","year":"2014","unstructured":"Jansen F, et al. MicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease. J Am Heart Assoc. 2014;3(6): e001249.","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"3213_CR17","volume":"12","author":"S Ramachandran","year":"2017","unstructured":"Ramachandran S, et al. Plasma microvesicle analysis identifies microRNA 129\u20135p as a biomarker of heart failure in univentricular heart disease. PLoS ONE. 2017;12(8): e0183624.","journal-title":"PLoS ONE"},{"issue":"10","key":"3213_CR18","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/oby.22298","volume":"26","author":"S Dimassi","year":"2018","unstructured":"Dimassi S, et al. Microparticle miRNAs as biomarkers of vascular function and inflammation response to aerobic exercise in obesity? Obesity (Silver Spring). 2018;26(10):1584\u201393.","journal-title":"Obesity (Silver Spring)"},{"key":"3213_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082009","author":"R Drula","year":"2020","unstructured":"Drula R, et al. MicroRNAs from liquid biopsy derived extracellular vesicles: recent advances in detection and characterization methods. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12082009.","journal-title":"Cancers (Basel)"},{"key":"3213_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13407","author":"P Siwaponanan","year":"2020","unstructured":"Siwaponanan P, et al. Enumeration and phenotyping of circulating microvesicles by flow cytometry and nanoparticle tracking analysis: plasma versus serum. Int J Lab Hematol. 2020. https:\/\/doi.org\/10.1111\/ijlh.13407.","journal-title":"Int J Lab Hematol"},{"issue":"9","key":"3213_CR21","volume":"7","author":"Z Liu","year":"2012","unstructured":"Liu Z, et al. The expression levels of plasma micoRNAs in atrial fibrillation patients. PLoS ONE. 2012;7(9): e44906.","journal-title":"PLoS ONE"},{"issue":"4","key":"3213_CR22","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.hrthm.2014.01.018","volume":"11","author":"DD McManus","year":"2014","unstructured":"McManus DD, et al. Relations between circulating microRNAs and atrial fibrillation: data from the Framingham Offspring Study. Heart Rhythm. 2014;11(4):663\u20139.","journal-title":"Heart Rhythm"},{"issue":"2","key":"3213_CR23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrcardio.2014.178","volume":"12","author":"X Luo","year":"2015","unstructured":"Luo X, Yang B, Nattel S. MicroRNAs and atrial fibrillation: mechanisms and translational potential. Nat Rev Cardiol. 2015;12(2):80\u201390.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"3213_CR24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.hrthm.2014.09.050","volume":"12","author":"DD McManus","year":"2015","unstructured":"McManus DD, et al. Plasma microRNAs are associated with atrial fibrillation and change after catheter ablation (the miRhythm study). Heart Rhythm. 2015;12(1):3\u201310.","journal-title":"Heart Rhythm"},{"issue":"14","key":"3213_CR25","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1161\/CIRCULATIONAHA.112.001207","volume":"127","author":"K Dawson","year":"2013","unstructured":"Dawson K, et al. MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. Circulation. 2013;127(14):1466\u201375.","journal-title":"Circulation"},{"issue":"6","key":"3213_CR26","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jjcc.2015.12.007","volume":"68","author":"T Soeki","year":"2016","unstructured":"Soeki T, et al. Relationship between local production of microRNA-328 and atrial substrate remodeling in atrial fibrillation. J Cardiol. 2016;68(6):472\u20137.","journal-title":"J Cardiol"},{"issue":"25","key":"3213_CR27","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1161\/CIRCULATIONAHA.120.052009","volume":"143","author":"O Shaihov-Teper","year":"2021","unstructured":"Shaihov-Teper O, et al. Extracellular vesicles from epicardial fat facilitate atrial fibrillation. Circulation. 2021;143(25):2475\u201393.","journal-title":"Circulation"},{"issue":"5","key":"3213_CR28","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0735-1097(99)00382-4","volume":"34","author":"C Aime-Sempe","year":"1999","unstructured":"Aime-Sempe C, et al. Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol. 1999;34(5):1577\u201386.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"3213_CR29","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3892\/etm.2013.899","volume":"5","author":"GJ Xu","year":"2013","unstructured":"Xu GJ, et al. Accelerated fibrosis and apoptosis with ageing and in atrial fibrillation: adaptive responses with maladaptive consequences. Exp Ther Med. 2013;5(3):723\u20139.","journal-title":"Exp Ther Med"},{"issue":"1","key":"3213_CR30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1161\/ATVBAHA.109.200956","volume":"31","author":"O Morel","year":"2011","unstructured":"Morel O, et al. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol. 2011;31(1):15\u201326.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"3213_CR31","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ijcard.2013.03.031","volume":"168","author":"L Jesel","year":"2013","unstructured":"Jesel L, et al. Microparticles in atrial fibrillation: a link between cell activation or apoptosis, tissue remodelling and thrombogenicity. Int J Cardiol. 2013;168(2):660\u20139.","journal-title":"Int J Cardiol"},{"key":"3213_CR32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cytogfr.2019.12.007","volume":"51","author":"C Ciardiello","year":"2020","unstructured":"Ciardiello C, et al. Large extracellular vesicles: size matters in tumor progression. Cytokine Growth Factor Rev. 2020;51:69\u201374.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"6","key":"3213_CR33","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.thromres.2011.07.013","volume":"128","author":"M Hayashi","year":"2011","unstructured":"Hayashi M, et al. Platelet activation and induction of tissue factor in acute and chronic atrial fibrillation: involvement of mononuclear cell-platelet interaction. Thromb Res. 2011;128(6):e113\u20138.","journal-title":"Thromb Res"},{"issue":"4","key":"3213_CR34","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cvr\/cvq357","volume":"89","author":"AM De Jong","year":"2011","unstructured":"De Jong AM, et al. Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation. Cardiovasc Res. 2011;89(4):754\u201365.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"3213_CR35","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/clc.23158","volume":"42","author":"P Siwaponanan","year":"2019","unstructured":"Siwaponanan P, et al. Altered profile of circulating microparticles in nonvalvular atrial fibrillation. Clin Cardiol. 2019;42(4):425\u201331.","journal-title":"Clin Cardiol"},{"issue":"1","key":"3213_CR36","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bbrc.2010.12.119","volume":"405","author":"Q Zhang","year":"2011","unstructured":"Zhang Q, Kandic I, Kutryk MJ. Dysregulation of angiogenesis-related microRNAs in endothelial progenitor cells from patients with coronary artery disease. Biochem Biophys Res Commun. 2011;405(1):42\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"Pt 11","key":"3213_CR37","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1113\/jphysiol.2010.201400","volume":"589","author":"JJ Ronkainen","year":"2011","unstructured":"Ronkainen JJ, et al. Ca2+-calmodulin-dependent protein kinase II represses cardiac transcription of the L-type calcium channel alpha(1C)-subunit gene (Cacna1c) by DREAM translocation. J Physiol. 2011;589(Pt 11):2669\u201386.","journal-title":"J Physiol"},{"issue":"3","key":"3213_CR38","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1161\/ATVBAHA.111.240341","volume":"32","author":"Y Higashikuni","year":"2012","unstructured":"Higashikuni Y, et al. The ATP-binding cassette transporter ABCG2 protects against pressure overload-induced cardiac hypertrophy and heart failure by promoting angiogenesis and antioxidant response. Arterioscler Thromb Vasc Biol. 2012;32(3):654\u201361.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"3213_CR39","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/1055-9965.EPI-06-0639","volume":"16","author":"KL Novik","year":"2007","unstructured":"Novik KL, et al. Genetic variation in H2AFX contributes to risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1098\u2013106.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"23","key":"3213_CR40","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1161\/CIRCULATIONAHA.110.958967","volume":"122","author":"Y Lu","year":"2010","unstructured":"Lu Y, et al. MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation. 2010;122(23):2378\u201387.","journal-title":"Circulation"},{"key":"3213_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-32637-1_1","volume":"1196","author":"N Kapodistrias","year":"2020","unstructured":"Kapodistrias N, Theocharopoulou G, Vlamos P. A hypothesis of circulating MicroRNAs\u2019 implication in high incidence of atrial fibrillation and other electrocardiographic abnormalities in cancer patients. Adv Exp Med Biol. 2020;1196:1\u20139.","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"3213_CR42","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCEP.114.001973","volume":"7","author":"DY Chiang","year":"2014","unstructured":"Chiang DY, et al. Loss of microRNA-106b-25 cluster promotes atrial fibrillation by enhancing ryanodine receptor type-2 expression and calcium release. Circ Arrhythm Electrophysiol. 2014;7(6):1214\u201322.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"3","key":"3213_CR43","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/cvr\/cvp130","volume":"83","author":"H Shan","year":"2009","unstructured":"Shan H, et al. Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc Res. 2009;83(3):465\u201372.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"3213_CR44","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s10495-011-0683-0","volume":"17","author":"J Fang","year":"2012","unstructured":"Fang J, et al. Overexpression of microRNA-378 attenuates ischemia-induced apoptosis by inhibiting caspase-3 expression in cardiac myocytes. Apoptosis. 2012;17(4):410\u201323.","journal-title":"Apoptosis"},{"issue":"7","key":"3213_CR45","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/cvr\/cvz236","volume":"116","author":"B Krist","year":"2020","unstructured":"Krist B, et al. miR-378a influences vascularization in skeletal muscles. Cardiovasc Res. 2020;116(7):1386\u201397.","journal-title":"Cardiovasc Res"},{"issue":"9","key":"3213_CR46","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.7150\/thno.22878","volume":"8","author":"J Yuan","year":"2018","unstructured":"Yuan J, et al. MicroRNA-378 suppresses myocardial fibrosis through a paracrine mechanism at the early stage of cardiac hypertrophy following mechanical stress. Theranostics. 2018;8(9):2565\u201382.","journal-title":"Theranostics"},{"issue":"21","key":"3213_CR47","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1161\/CIRCULATIONAHA.112.000882","volume":"127","author":"J Ganesan","year":"2013","unstructured":"Ganesan J, et al. MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation. 2013;127(21):2097\u2013106.","journal-title":"Circulation"},{"key":"3213_CR48","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1479-5876-12-90","volume":"12","author":"H Liu","year":"2014","unstructured":"Liu H, et al. Comparative expression profiles of microRNA in left and right atrial appendages from patients with rheumatic mitral valve disease exhibiting sinus rhythm or atrial fibrillation. J Transl Med. 2014;12:90.","journal-title":"J Transl Med"},{"key":"3213_CR49","volume":"6","author":"JX Wang","year":"2015","unstructured":"Wang JX, et al. MicroRNA-532\u20133p regulates mitochondrial fission through targeting apoptosis repressor with caspase recruitment domain in doxorubicin cardiotoxicity. Cell Death Dis. 2015;6: e1677.","journal-title":"Cell Death Dis"},{"issue":"5\u20136","key":"3213_CR50","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s10495-020-01609-1","volume":"25","author":"DNK Chandrasekera","year":"2020","unstructured":"Chandrasekera DNK, et al. Upregulation of microRNA-532 enhances cardiomyocyte apoptosis in the diabetic heart. Apoptosis. 2020;25(5\u20136):388\u201399.","journal-title":"Apoptosis"},{"issue":"4","key":"3213_CR51","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1161\/ATVBAHA.114.305176","volume":"35","author":"T Huan","year":"2015","unstructured":"Huan T, et al. Dissecting the roles of microRNAs in coronary heart disease via integrative genomic analyses. Arterioscler Thromb Vasc Biol. 2015;35(4):1011\u201321.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"3213_CR52","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1159\/000445588","volume":"38","author":"M Tan","year":"2016","unstructured":"Tan M, et al. Thrombin stimulated platelet-derived exosomes inhibit platelet-derived growth factor receptor-beta expression in vascular smooth muscle cells. Cell Physiol Biochem. 2016;38(6):2348\u201365.","journal-title":"Cell Physiol Biochem"},{"issue":"3","key":"3213_CR53","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1378\/chest.06-2039","volume":"131","author":"A Choudhury","year":"2007","unstructured":"Choudhury A, et al. Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to p-selectin and antithrombotic therapy. Chest. 2007;131(3):809\u201315.","journal-title":"Chest"},{"issue":"6","key":"3213_CR54","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.amjcard.2007.04.040","volume":"100","author":"S Ederhy","year":"2007","unstructured":"Ederhy S, et al. Levels of circulating procoagulant microparticles in nonvalvular atrial fibrillation. Am J Cardiol. 2007;100(6):989\u201394.","journal-title":"Am J Cardiol"},{"issue":"1","key":"3213_CR55","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1080\/21691401.2019.1671432","volume":"47","author":"L Liu","year":"2019","unstructured":"Liu L, et al. Exosomal miR-320d derived from adipose tissue-derived MSCs inhibits apoptosis in cardiomyocytes with atrial fibrillation (AF). Artif Cells Nanomed Biotechnol. 2019;47(1):3976\u201384.","journal-title":"Artif Cells Nanomed Biotechnol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-021-03213-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-021-03213-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-021-03213-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T05:22:38Z","timestamp":1641187358000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-021-03213-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,3]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3213"],"URL":"https:\/\/doi.org\/10.1186\/s12967-021-03213-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,3]]},"assertion":[{"value":"21 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol for this study was approved by the Siriraj Institutional Review Board (SIRB) (COA no. Si 489\/2019), and complied with the principles set forth in the Declaration of Helsinki (1964) and all of its subsequent amendments. All study participants provided written informed consent prior to inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no personal or professional conflicts of interest, and no financial support from the companies that produce and\/or distribute the drugs, devices, or materials described in this report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}